Guilford Aggrastat PCI Superiority Trial Planned For 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to meet with FDA shortly to discuss design of a placebo-controlled superiority trial for percutaneous coronary intervention. Aggrastat sales decline beginning to slow; sales could improve in the second half of the year, Guilford says.